NCT04702425View on ClinicalTrials.gov

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

PHASE1TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 23, 2021

Primary Completion Date

July 23, 2024

Study Completion Date

July 23, 2024

Conditions
Non-Hodgkin Lymphoma (NHL)Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)
Interventions
DRUG

VOB560

Powder for concentrate for solution for infusion

DRUG

MIK665

Concentrate for solution for infusion

Trial Locations (9)

9000

Novartis Investigative Site, Ghent

20089

Novartis Investigative Site, Rozzano

39008

Novartis Investigative Site, Santander

77030

Uni of TX MD Anderson Cancer Cntr UT MD Anderson Cancer Ctr, Houston

6423906

Novartis Investigative Site, Tel Aviv

FIN-00029

Novartis Investigative Site, HUS

Unknown

Novartis Investigative Site, Hong Kong

411 8777

Novartis Investigative Site, Sunto Gun

03080

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY